OsteoGeneX Inc., based in Kansas City, MO., is an early-stage biopharmaceutical company focused on becoming a worldwide leading developer and marketer of its proprietary OsteoX601. The first true oral therapeutic class of bone anabolic drugs targeting Sclerostin (SOST). Its immediate objective is to develop a first-generation small molecule therapeutic to treat moderate & severe osteoporosis. The Company is commercializing recent findings showing bone-forming osteoblasts can be modulated directly via a newly discovered ligand-receptor complex to regulate bone density in skeletal tissue. These seminal findings form the basis for OsteoGeneX's proprietary OsteoX601 Technology and its GeneX Therapeutic product platform that represents a new class of bone anabolic agents aimed at modulating the density and quality of bone for osteoporosis, skeletal fracture repair and other disorders where skeletal homeostasis is disrupted.
